USA - NASDAQ:PLRX - US7291391057 - Common Stock
We assign a fundamental rating of 1 out of 10 to PLRX. PLRX was compared to 191 industry peers in the Pharmaceuticals industry. PLRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PLRX does not seem to be growing, but still is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.03% | ||
| ROE | -94.04% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.36 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 12.99 | ||
| Quick Ratio | 12.99 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.81
+0.06 (+3.43%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.5 | ||
| P/tB | 0.5 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.03% | ||
| ROE | -94.04% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 78.46% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 12.99 | ||
| Quick Ratio | 12.99 | ||
| Altman-Z | -4.36 |
ChartMill assigns a fundamental rating of 1 / 10 to PLRX.
ChartMill assigns a valuation rating of 0 / 10 to PLIANT THERAPEUTICS INC (PLRX). This can be considered as Overvalued.
PLIANT THERAPEUTICS INC (PLRX) has a profitability rating of 0 / 10.
The Earnings per Share (EPS) of PLIANT THERAPEUTICS INC (PLRX) is expected to grow by 22.99% in the next year.